Literature DB >> 8387497

Two isoforms of prostaglandin E receptor EP3 subtype. Different COOH-terminal domains determine sensitivity to agonist-induced desensitization.

M Negishi1, Y Sugimoto, A Irie, S Narumiya, A Ichikawa.   

Abstract

We recently identified two isoforms of mouse prostaglandin (PG) E receptor EP3 subtype, EP3 alpha and EP 3 beta, which are produced by alternative splicing and different only in the carboxyl-terminal domain (Sugimoto, Y., Negishi, M., Hayashi, Y., Namba, Y., T., Honda, A., Watabe, A., Hirata, M., Narumiya, S., and Ichikawa, A. (1993) J. Biol. Chem. 268, 2712-2718). We examined here agonist-induced desensitization of the two isoforms using Chinese hamster ovary cells stably expressing these isoforms. Exposure of the EP3 alpha isoform to PGE2 for 30 min did not change maximal response but increased PGE2 concentration needed to inhibit forskolin-induced cAMP accumulation in the cells. Further exposure of this isoform to PGE2 suppressed the maximal response as well as sensitivity to PGE2 in a time-dependent manner; after 24-h exposure, it elicited only 50% of the maximal response of the control cells. Consistent with these results, short term exposure sequestered the EP3 alpha isoform away from the cell surface and long term incubation decreased the total receptor number in the cells. In contrast, exposure of the EP3 beta isoform to PGE2 did not affect its dose-response curve for PGE2, and no sequestration or decrease in the receptor number was observed in this isoform. Thus, alternative splicing produced the two isoforms with different carboxyl-terminal domains, which are different in sensitivity to agonist-induced desensitization.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8387497

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  25 in total

1.  The human 5-HT7 serotonin receptor splice variants: constitutive activity and inverse agonist effects.

Authors:  Kurt A Krobert; Finn Olav Levy
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

2.  Identification of a region of the C-terminal domain involved in short-term desensitization of the prostaglandin EP4 receptor.

Authors:  M Bastepe; B Ashby
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

3.  Role of the ERC motif in the proximal part of the second intracellular loop and the C-terminal domain of the human prostaglandin F2alpha receptor (hFP-R) in G-protein coupling control.

Authors:  Andrea Pathe-Neuschäfer-Rube; Frank Neuschäfer-Rube; Gerhard P Püschel
Journal:  Biochem J       Date:  2005-05-15       Impact factor: 3.857

4.  Alternative RNA splicing of the human endothelin-A receptor generates multiple transcripts.

Authors:  Y Miyamoto; T Yoshimasa; H Arai; K Takaya; Y Ogawa; H Itoh; K Nakao
Journal:  Biochem J       Date:  1996-02-01       Impact factor: 3.857

5.  Molecular cloning and expression of human EP3 receptors: evidence of three variants with differing carboxyl termini.

Authors:  J W Regan; T J Bailey; J E Donello; K L Pierce; D J Pepperl; D Zhang; K M Kedzie; C E Fairbairn; A M Bogardus; D F Woodward
Journal:  Br J Pharmacol       Date:  1994-06       Impact factor: 8.739

6.  PGE2-EP3 signaling exacerbates intracerebral hemorrhage outcomes in 24-mo-old mice.

Authors:  Jenna L Leclerc; Andrew S Lampert; Matthew A Diller; Sylvain Doré
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-04-15       Impact factor: 4.733

7.  Prostaglandin E2 elicits a morphological change in cultured orbital fibroblasts from patients with Graves ophthalmopathy.

Authors:  T J Smith; H S Wang; M G Hogg; R C Henrikson; C R Keese; I Giaever
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

8.  Characterization of the PGE2 receptor subtype in bovine chondrocytes in culture.

Authors:  A J de Brum-Fernandes; S Morisset; G Bkaily; C Patry
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

9.  The EP3 Receptor: Exploring a New Target for Type 2 Diabetes Therapeutics.

Authors:  Joshua C Neuman; Michelle E Kimple
Journal:  J Endocrinol Diabetes Obes       Date:  2013 Jul-Sep

10.  Prostaglandin E2 Reduces Cardiac Contractility via EP3 Receptor.

Authors:  Xiaosong Gu; Jiang Xu; Liping Zhu; Timothy Bryson; Xiao-Ping Yang; Edward Peterson; Pamela Harding
Journal:  Circ Heart Fail       Date:  2016-08       Impact factor: 8.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.